https://www.selleckchem.com/products/ml364.html
Conclusions NGLY1-CDDG should be considered in patients with developmental disability associated with a hyperkinetic movement disorder and alacrimia/hypolacrima. Absence of the latter two symptoms does not rule out this diagnosis. © 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley Sons Ltd on behalf of SSIEM.Background Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common congenital disorder of glycosylation (CDG). Hypoglycemia has been reported in various CDG including PMM2-CDG. The frequency
Like
Comment
Share
